Cargando…
CDK4/6 inhibition in breast cancer: current practice and future directions
The cyclin D/cyclin-dependent kinases 4 and 6 (CDK4/6)–retinoblastoma protein (RB) pathway plays a key role in the proliferation of both normal breast epithelium and breast cancer cells. A strong rationale for inhibiting CDK4/6 in breast cancers has been present for many years. However, potent and s...
Autores principales: | Pernas, Sonia, Tolaney, Sara M., Winer, Eric P., Goel, Shom |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6050811/ https://www.ncbi.nlm.nih.gov/pubmed/30038670 http://dx.doi.org/10.1177/1758835918786451 |
Ejemplares similares
-
CDK4/6 inhibition: the late harvest cycle begins
por: Goel, Shom, et al.
Publicado: (2016) -
PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer
por: Ali, Lestat R., et al.
Publicado: (2023) -
Correction: PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer
por: Ali, Lestat R., et al.
Publicado: (2023) -
Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer
por: Watt, April C., et al.
Publicado: (2022) -
Is there a role for CDK 4/6 inhibitors in breast cancer brain metastases?
por: Schlam, Ilana, et al.
Publicado: (2021)